Tirzepatide vs Semaglutide: Which Is Better for Weight Loss in 2026?

By RxPickr Editorial Team

You've done some research. Maybe your doctor mentioned both options, or a telehealth intake form asked which medication you'd prefer. Either way, you're trying to figure out whether tirzepatide or semaglutide is the better fit — and the honest answer is: it depends on what you're optimizing for.

Both are weekly injectable GLP-1 medications. Both require a prescription. Both have helped a significant number of people lose meaningful amounts of weight. But they're not the same drug, they don't produce identical results, and they're not priced the same. Here's what the clinical data and real-world costs actually show.

How They Work Differently

Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut releases after eating, signaling to your brain that you're full and slowing gastric emptying. The result: you eat less, feel satisfied sooner, and your body adjusts its appetite set point over time.

Tirzepatide takes a different approach. It's a dual GIP/GLP-1 receptor agonist, meaning it activates two hormone pathways instead of one. GIP (glucose-dependent insulinotropic polypeptide) works alongside GLP-1 to amplify insulin response, reduce fat storage, and may enhance the appetite-suppressing effects. This dual mechanism is widely hypothesized to explain why tirzepatide has produced greater weight loss than semaglutide in head-to-head studies, though the precise mechanistic contributions continue to be studied (NEJM, 2025).

For weight loss specifically:

• Semaglutide is sold as Wegovy (2.4mg weekly injection). Ozempic uses the same active ingredient but is approved for type 2 diabetes, not weight management.
• Tirzepatide is sold as Zepbound for weight loss. Mounjaro is the same molecule, approved for type 2 diabetes.

Compounded versions of both exist through telehealth providers. These use the same active ingredient but are not FDA-approved as finished products — a meaningful distinction covered in more detail in our compounded vs brand-name semaglutide guide.

Head-to-Head: What SURMOUNT-5 Found

For years, comparing tirzepatide and semaglutide meant cobbling together separate trials with different patient populations and protocols. In 2025, that changed.

The SURMOUNT-5 trial was the first randomized head-to-head study comparing the two medications directly in adults with obesity (without diabetes). The results were published in the New England Journal of Medicine in May 2025 (NEJM, 2025).

At 72 weeks, tirzepatide produced a mean body weight loss of 20.2% versus 13.7% for semaglutide — a difference of about 6.5 percentage points (NEJM, 2025).

The trial also found that tirzepatide participants were significantly more likely than semaglutide participants to achieve weight reductions of at least 10%, 15%, 20%, and 25% (NEJM, 2025).

Outcome	Tirzepatide	Semaglutide
Mean total weight loss (72 wks)	20.2%	13.7%
≥10% body weight loss	Superior (p<0.001)	—
≥15% body weight loss	Superior (p<0.001)	—

Source: SURMOUNT-5, NEJM 2025

Put concretely: in someone who starts at 250 lbs, a 20.2% loss is roughly 50 lbs. At 13.7%, that's about 34 lbs. Both are real, meaningful outcomes. But the gap is real too.

It's worth noting that a 13.7% mean weight loss is a clinically significant outcome. This isn't a story of one medication working and the other not — both have shown meaningful results in clinical trials. Tirzepatide just tends to produce more.

Side Effects: More Alike Than Different

Both medications share a similar side effect profile because both act on the GLP-1 pathway. The most common issues are gastrointestinal: nausea, vomiting, constipation, and diarrhea. These are primarily mild-to-moderate and tend to peak during dose escalation (Wegovy prescribing information, DailyMed/NLM; Zepbound prescribing information, DailyMed/NLM).

Starting slow and escalating the dose gradually is the standard approach to managing GI side effects for both medications. Most people find the side effects ease significantly once they reach their maintenance dose.

In SURMOUNT-5, GI side effect rates were broadly comparable between the two drugs (NEJM, 2025). If you struggled with nausea on semaglutide, switching to tirzepatide isn't likely to solve that. The dual mechanism means more efficacy, not a meaningfully gentler tolerance profile.

For a deeper look at managing GI side effects on either medication, see our GLP-1 side effects guide.

Cost: The Real Deciding Factor for Most People

Brand-name prices are high for both. But tirzepatide has a meaningful cost advantage at list price.

Medication	Brand name	Approx. list price	With savings card/insurance
Semaglutide 2.4mg	Wegovy	~$1,350/month	$25–$100/month copay with coverage
Tirzepatide	Zepbound	~$1,060–$1,500+/month (varies by dose)	Lilly savings card may reduce cost significantly for eligible patients
Compounded semaglutide	N/A	~$150–$300/month (via telehealth)	N/A (cash only)
Compounded tirzepatide	N/A	~$250–$450/month (via telehealth)	N/A (cash only)

Prices are approximate, vary by dose, and are subject to change. Telehealth pricing based on provider websites as of April 2026. Compounded medications are not FDA-approved as finished products.

A few things worth knowing here:

Zepbound's list price runs lower than Wegovy's, and Eli Lilly has maintained a savings program that can bring out-of-pocket costs down significantly for cash-pay patients. If you have good insurance that covers GLP-1s for weight loss, both are likely to be affordable. As of early 2026, many commercial plans still exclude Wegovy and Zepbound for weight loss, and coverage varies widely by employer — verify your plan's current formulary before assuming coverage.

Compounded semaglutide became widely available through telehealth providers during the FDA shortage period. As of early 2026, the regulatory status of compounded GLP-1s continues to evolve. If you're considering compounded options, check the current status with your provider — and see our GLP-1 without insurance guide for the full picture on paying out of pocket.

Who Should Choose Semaglutide

Semaglutide may be the better starting point if:

• You have insurance that covers Wegovy. Semaglutide has been on the market longer, has more established prior authorization pathways at many insurers, and your plan may specifically cover it.
• Budget is your primary constraint. Compounded semaglutide through telehealth providers typically runs $150–$300/month, making it the more accessible option if tirzepatide isn't available compounded in your state or if prices for compounded tirzepatide are higher.
• You've already had positive results on semaglutide and are at a stable dose with good tolerability. If it's working, changing medications may introduce unnecessary risk.
• Your provider has more experience with semaglutide. Wegovy has been available since 2021. Many prescribers and telehealth platforms have more established protocols for it.

Who Should Choose Tirzepatide

Tirzepatide may be the better fit if:

• You want the highest probability of significant weight loss. The SURMOUNT-5 data makes this case directly. If your goal is maximum efficacy and cost is manageable, tirzepatide is the stronger evidence-based choice for most people.
• You tried semaglutide and the results were modest. Some people are partial responders to GLP-1-only agonism. Adding GIP receptor activation may produce a better outcome.
• You're paying out of pocket and brand-name is on the table. Zepbound's list price and savings card options may make brand-name tirzepatide more accessible than brand-name semaglutide.
• You have type 2 diabetes alongside obesity. Mounjaro is approved for both, and some prescribers prefer tirzepatide for this population given its metabolic profile. Talk to your doctor.

Neither medication is right for everyone. Semaglutide isn't a consolation prize — it's a well-studied treatment with established clinical trial data showing meaningful weight loss for many people. The choice often comes down to insurance coverage, access, cost, and your specific medical history.

How to Access Each Medication via Telehealth

Most telehealth providers in the GLP-1 space prescribe one or both options, depending on your state, your clinical profile, and what they have access to.

For tirzepatide:

LillyDirect is Eli Lilly's direct-to-patient program and one of the only ways to get brand-name Zepbound through a telehealth-style experience. It connects patients with independent telehealth providers and pharmacy partners.

Mochi Health specializes in GLP-1 prescriptions and offers both tirzepatide and semaglutide. They include ongoing provider support and are available in most states.

For semaglutide:

Ro offers brand-name Wegovy with insurance support and can handle prior authorization in many states. They also offer compounded semaglutide for cash-pay patients (not FDA-approved as a finished product).

Henry Meds is one of the more affordable telehealth options and offers both compounded semaglutide and compounded tirzepatide (not FDA-approved as finished products), depending on state availability.

Not sure which provider fits your situation? Answer a few questions and we'll match you with the best option based on your budget, insurance, and medication preference.

The Bottom Line

Tirzepatide outperformed semaglutide in the first direct head-to-head trial, producing meaningfully greater average weight loss at 72 weeks. If efficacy is your top priority and cost is workable, the evidence tilts toward tirzepatide.

But semaglutide is not a weak alternative. For many people, insurance coverage, familiarity, or cost will make it the practical choice — and there's nothing wrong with starting there.

The right answer is the one you can actually access, afford, and stick with. Both medications require a prescription and long-term commitment to see results. Consult with a licensed healthcare provider who can review your full medical history before deciding.

For more context on cost and access, see our guides on GLP-1 without insurance and the cheapest semaglutide options online.

---

GLP-1 medications require a prescription. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Compounded semaglutide and tirzepatide formulations use the same active ingredients as brand-name products but are not FDA-approved as finished products.